ताज़ा खबर
होम पर वापस
समाचार2 मिनट पढ़ें

Today's Trending डेस्क

Semaglutide: ताज़ा अपडेट

The Times of India और अन्य स्रोतों की रिपोर्टिंग के बाद Semaglutide प्रमुख खबर बन गया है।

फ़ोटो: Ophthalmology Advisor. Image shown via the original publisher or news index. All rights belong to the respective copyright holder.

साझा करें𝕏fWTin
Semaglutide: ताज़ा अपडेट

Semaglutide ने The Times of India की प्रारंभिक रिपोर्टिंग के बाद व्यापक ध्यान आकर्षित किया है।

संबंधित कवरेज

Semaglutide पर रुचि दर्शाती है कि कैसे एक खबर तेजी से वैश्विक सुर्खियों में आ सकती है। कम से कम 2 प्रकाशनों ने रिपोर्ट दी है।

मीडिया क्या बता रहा है

Today's Trending इस कहानी पर नज़र रखेगा और नई जानकारी मिलने पर अपडेट करेगा।

स्रोतित अंश

“Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that…”

“Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating…”


संबंधित कवरेज

1. ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian…

स्रोत: The Times of India

पूरी कहानी पढ़ें →

2. A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG)…

स्रोत: The South First

पूरी कहानी पढ़ें →

हमारे नेटवर्क से

ESG helps faster short-term weight loss than oral meds: AIG study

Hyderabad: At a time when weight loss medicines have become a rage, a new study by the Asian Institute of Gastroenterology has found that Endoscopic Sleeve Gastroplasty (ESG), a non-surgical procedure, helped patients lose weight faster than oral semaglutide tablets in the short term. After a year, though, the difference narrowed.The AIG Hospitals study has been published in the peer-reviewed journal Endoscopy.As part of the study, researchers Dr D Nageshwar Reddy, Dr Nitin Jagtap, and Dr Rakesh Kalpala, compared 150 adults with obesity treated between January 2024 and April 2025. Around 50 patients underwent ESG, while 100 received oral semaglutide 14 mg along with standard lifestyle modification. At six months, patients who underwent ESG achieved an average total body weight loss of 12.72%, compared with 8.67% among those taking oral semaglutide. Around 70% of ESG patients lost at leas…

The Times of India

A procedure or a pill? Hyderabad researchers compare two obesity treatments in a first-of-its-kind study

Synopsis: A new study from Hyderabad's AIG Hospitals compares Endoscopic Sleeve Gastroplasty (ESG) with oral semaglutide in treating obesity. Researchers found ESG produced greater weight loss at six months, while oral semaglutide largely caught up after one year. The findings highlight how treatment choice depends on patient goals, convenience and long-term care. An obese patient in Hyderabad asked a doctor a question that has become very common in recent times, "Should I undergo a procedure, or should I take a tablet?" Earlier, diet sheets and gym routines used to dominate conversations about obesity. Surgery waited at the far end, reserved for patients who had tried everything else. Now, that map has shifted. Patients weigh the stomach procedure against a hormone tablet. No one had tested the two against each other in the same group until doctors at AIG Hospitals in Hyderabad ran that…

The South First

और कहानियाँ